Effects of antiarrhythmic drugs on phospholipid metabolism in Jurkat T cells. The potassium channel blocker, clofilium, specifically increases phosphatidylserine synthesis.
Five antiarrhythmic drugs (bretylium, clofilium, propranolol, N-acetylprocainamide and amiodarone) were tested for their ability to modify phospholipid metabolism in Jurkat T lymphocytes. The five drugs, decreased in a dose-dependent mode the biosynthesis of both phosphatidylcholine and phosphatidylethanolamine, this effect was essentially due to impairment of either choline or ethanolamine uptake by the cells. The efficiency of the drugs to inhibit phosphatidylcholine and phosphatidylethanolamine synthesis was in the order: clofilium greater than amiodarone much greater than propranolol = bretylium much greater than N-acetylprocainamide. The IC50 varied from 3-5 microM for clofilium to greater than 200 microM for N-acetylprocainamide. In contrast, only clofilium, a voltage-gated K(+)-channel blocker, was able to increase phosphatidylserine synthesis with an EC50 = 50 microM. The effect of clofilium on phosphatidylserine synthesis thus mimics the effect of three other K(+)-channel blockers, quinine, 4-aminopyridine and tetraethylammonium, suggesting close relationships between phosphatidylserine synthesis and K+ channel activity.
Aussel
C
C
INSERM U210, Immunologie Cellulaire et Moléculaire, Faculté de Médecine (Pasteur), Nice, France.
Pelassy
C
C
D000120:Acecainide / Q000494:pharmacology; D000638:Amiodarone / Q000494:pharmacology; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology*; D001949:Bretylium Compounds / Q000494:pharmacology; D002262:Carboxy-Lyases / Q000378:metabolism; D002794:Choline / Q000378:metabolism; D003653:Decarboxylation; D004305:Dose-Response Relationship, Drug; D019856:Ethanolamine; D004983:Ethanolamines / Q000378:metabolism; D006801:Humans; D010713:Phosphatidylcholines / Q000096:biosynthesis; D010714:Phosphatidylethanolamines / Q000096:biosynthesis; D010718:Phosphatidylserines / Q000096:biosynthesis; D010743:Phospholipids / Q000378:metabolism*; D011433:Propranolol / Q000494:pharmacology; D000644:Quaternary Ammonium Compounds / Q000494:pharmacology; D013601:T-Lymphocytes / Q000187:drug effects / Q000378:metabolism*
D000889:Anti-Arrhythmia Agents; D001949:Bretylium Compounds; D004983:Ethanolamines; D010713:Phosphatidylcholines; D010714:Phosphatidylethanolamines; D010718:Phosphatidylserines; D010743:Phospholipids; D000644:Quaternary Ammonium Compounds; D019856:Ethanolamine; C022799:clofilium; D000120:Acecainide; D011433:Propranolol; D002262:Carboxy-Lyases; D000638:Amiodarone; D002794:Choline; C045166:bretylium